Following are selected publications that JASIN team members have contributed towards.

2010

• A Three Dimensional Pharmacophore Model for Human EP3 Antagonists
  Mishra, RK, Singh, J. J Chem Inf. Modl. 2010, 50, 1502-1509.

• Chirality and Biological Activity.
  Singh, J, Hagen, T. Chapter 21, Burger's Medicinal Chemistry, Drug Discovery and Development, 7th Edition, Abraham, D and Rotella, D (Editors), Wiley and Sons. July 2010.
  

• EP3 receptor antagonists: improving safety in the antiplatelet therapy field.
  Singh, J, Kiselyov, AS. (Invited Review), Drugs of Future, 2010, 35(1), 21-31.

• Discovery of DG-051 as a Novel Leukotriene A4 Hydrolase Inhibitor of Leukotriene B4 Biosynthesis.
  Sandanayaka, V, et.al. J Med Chem. 2010, 53(2), 573-585.

• Structure-Activity Relationship Studies Leading to the Identification of DG-041, a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Anti-Platelet Agent that Does Not Prolong Bleeding.
  Singh, J,. et.al. J Med Chem. 2010, 53, 18–36.

• Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
  Burgin, A,. et.al. Nature Biotechnology 2010, 28(1), 63-71.

• Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.
  Butchbach, M. et.al. Human Molecular Genetics, 2010, 19(3), 454–467.

• Regiospecific synthesis of 3-alkyl-4-hydroxybenzoimidazoles as intermediates for expedient approach to potent EP3 receptor antagonists.
  Zeller, W. et.al. Tett Letters 2010, 51, 1380-82.

• A general approach to indole-7-yl derivatives of isoxazole, oxadiazole, thiadiazole and pyrazole.
  Polozov, A.M. et.al. Tett. Letters, 2010, 51, 575–578.

• 1,7-Disubstituted Oxyindoles Are Potent and Selective EP3 Receptor Antagonists. Zhou, N. et.al.
  Bioorg Med Chem Letters. 2010, 20, 2658–2664.

 

2009

• DcpS as a Therapeutic Target for Spinal Muscular Atrophy.
  Singh, J. et.al. ACS Chemical Biology. 2008, 3, 711- 722.

• Antagonists of The EP3 Receptor for Prostaglandin E2 Are Novel Anti-Platelet Agents That Do Not Prolong Bleeding.
  Singh, J. et.al. ACS Chem Biology. 2009, 4(2), 115–126.

• Development of a Scalable Synthetic Process for DG-051B, a First-in-Class Inhibitor of LTA4H.
  Enache, L.A. et.al. Org Proc Res Dev, 2009, 13(6), 1177-1184

 

2008

• Synthesis and Biological Evaluation of Novel 2,4-Diaminoquinazoline Derivatives as SMN2 Promoter Activators for the Potential Treatment of Spinal Muscular Atrophy.
  Thurmond, J. et.al. J Med Chem. 2008 51, 449-469.

 

2007

• Development of a Scalable Synthetic Process for DG-041, a Potent EP3 Receptor Antagonist.
  Ziger, S . et.al. Org Proc Res Dev. 2007, 11, 747-753